Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
Merck
Harvard Business School
McKesson

Last Updated: August 8, 2022

Investigational Drug Information for IRX-5183


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for IRX-5183?

IRX-5183 is an investigational drug.

There have been 12 clinical trials for IRX-5183. The most recent clinical trial was a Phase 2 trial, which was initiated on November 15th 2021.

The most common disease conditions in clinical trials are Carcinoma, Squamous Cell, Carcinoma, and Squamous Cell Carcinoma of Head and Neck. The leading clinical trial sponsors are Brooklyn ImmunoTherapeutics, LLC, IRX Therapeutics, and National Cancer Institute (NCI).

There are ten US patents protecting this investigational drug and seventy-one international patents.

Recent Clinical Trials for IRX-5183
TitleSponsorPhase
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)iRenix Medical, Inc.Phase 3
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerBrooklyn ImmunoTherapeutics, LLCPhase 2
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerMerck Sharp & Dohme Corp.Phase 2

See all IRX-5183 clinical trials

Clinical Trial Summary for IRX-5183

Top disease conditions for IRX-5183
Top clinical trial sponsors for IRX-5183

See all IRX-5183 clinical trials

US Patents for IRX-5183

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IRX-5183 See Plans and Pricing Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
IRX-5183 See Plans and Pricing Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Io Therapeutics, Inc. (Santa Ana, CA) See Plans and Pricing
IRX-5183 See Plans and Pricing Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
IRX-5183 See Plans and Pricing RAR selective agonists in combination with immune modulators for cancer immunotherapy Io Therapeutics, Inc. (Almeda, TX) See Plans and Pricing
IRX-5183 See Plans and Pricing Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy lo Therapeutics, Inc. (Houston, TX) See Plans and Pricing
IRX-5183 See Plans and Pricing Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Syros Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IRX-5183

Drugname Country Document Number Estimated Expiration Related US Patent
IRX-5183 Australia AU2016243702 2035-03-31 See Plans and Pricing
IRX-5183 Australia AU2022200059 2035-03-31 See Plans and Pricing
IRX-5183 Brazil BR112017020745 2035-03-31 See Plans and Pricing
IRX-5183 Canada CA2981518 2035-03-31 See Plans and Pricing
IRX-5183 China CN107613969 2035-03-31 See Plans and Pricing
IRX-5183 European Patent Office EP3277272 2035-03-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.